168 related articles for article (PubMed ID: 36169712)
1. The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity.
García-Robles A; Solaz-García Á; Verdú-Andrés J; Andrés JLP; Cañada-Martínez AJ; Pericás CC; Ponce-Rodriguez HD; Vento M; González PS
Eur J Pediatr; 2022 Dec; 181(12):4175-4182. PubMed ID: 36169712
[TBL] [Abstract][Full Text] [Related]
2. Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity.
Lee TC; Charles BG; Steer PA; Flenady VJ
Ther Drug Monit; 1996 Jun; 18(3):288-93. PubMed ID: 8738770
[TBL] [Abstract][Full Text] [Related]
3. Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants.
Khanna NN; Bada HS; Somani SM
J Pediatr; 1980 Mar; 96(3 Pt 1):494-9. PubMed ID: 7359248
[TBL] [Abstract][Full Text] [Related]
4. Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy.
Dobson NR; Liu X; Rhein LM; Darnall RA; Corwin MJ; McEntire BL; Ward RM; James LP; Sherwin CM; Heeren TC; Hunt CE
Br J Clin Pharmacol; 2016 Sep; 82(3):754-61. PubMed ID: 27145974
[TBL] [Abstract][Full Text] [Related]
5. Caffeine therapy for apnea of prematurity.
Schmidt B; Roberts RS; Davis P; Doyle LW; Barrington KJ; Ohlsson A; Solimano A; Tin W;
N Engl J Med; 2006 May; 354(20):2112-21. PubMed ID: 16707748
[TBL] [Abstract][Full Text] [Related]
6. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring.
Charles BG; Townsend SR; Steer PA; Flenady VJ; Gray PH; Shearman A
Ther Drug Monit; 2008 Dec; 30(6):709-16. PubMed ID: 19057373
[TBL] [Abstract][Full Text] [Related]
7. Serum caffeine concentrations in preterm infants: a retrospective study.
Sugino M; Kuboi T; Noguchi Y; Nishioka K; Tadatomo Y; Kawaguchi N; Sadamura T; Nakano A; Konishi Y; Koyano K; Nakamura S; Okada H; Itoh S; Kusaka T
Sci Rep; 2023 Jun; 13(1):10305. PubMed ID: 37365252
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea.
Guo A; Zhu Z; Xue J; Di X; Fan J; Huang L; Zhao P; Hu X; Xie H
J Clin Pharm Ther; 2020 Dec; 45(6):1414-1421. PubMed ID: 32737938
[TBL] [Abstract][Full Text] [Related]
9. Caffeine for apnea of prematurity: a neonatal success story.
Kreutzer K; Bassler D
Neonatology; 2014; 105(4):332-6. PubMed ID: 24931325
[TBL] [Abstract][Full Text] [Related]
10. Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range?
Chung J; Tran Lopez K; Amendolia B; Bhat V; Nakhla T; Slater-Myer L; Saslow J; Aghai ZH
J Matern Fetal Neonatal Med; 2022 Feb; 35(3):551-555. PubMed ID: 32079435
[TBL] [Abstract][Full Text] [Related]
11. Acute hemodynamic effects of caffeine administration in premature infants.
Soloveychik V; Bin-Nun A; Ionchev A; Sriram S; Meadow W
J Perinatol; 2009 Mar; 29(3):205-8. PubMed ID: 19052555
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of caffeine therapy for apnea of prematurity.
Schmidt B; Roberts RS; Davis P; Doyle LW; Barrington KJ; Ohlsson A; Solimano A; Tin W;
N Engl J Med; 2007 Nov; 357(19):1893-902. PubMed ID: 17989382
[TBL] [Abstract][Full Text] [Related]
13. Sequelae of caffeine treatment in preterm infants with apnea.
Gunn TR; Metrakos K; Riley P; Willis D; Aranda JV
J Pediatr; 1979 Jan; 94(1):106-9. PubMed ID: 363996
[TBL] [Abstract][Full Text] [Related]
14. [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].
Xie JB; Lin XZ
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jul; 24(7):832-837. PubMed ID: 35894202
[TBL] [Abstract][Full Text] [Related]
15. Developmental aspects of percutaneous caffeine absorption in premature infants.
Amato M; Hüppi P; Isenschmid M; Schneider H
Am J Perinatol; 1992; 9(5-6):431-4. PubMed ID: 1418150
[TBL] [Abstract][Full Text] [Related]
16. [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate].
Ducrocq S; Biran-Mucignat V; Boelle PY; Lebas F; Baudon JJ; Gold F
Arch Pediatr; 2006 Oct; 13(10):1299-304. PubMed ID: 16919922
[TBL] [Abstract][Full Text] [Related]
17. National and international guidelines for neonatal caffeine use: Are they evidenced-based?
Eichenwald EC
Semin Fetal Neonatal Med; 2020 Dec; 25(6):101177. PubMed ID: 33214064
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.
Fang S; Sherwood RA; Gamsu HR; Marsden JT; Peters TJ; Greenough A
Eur J Pediatr; 1998 May; 157(5):406-9. PubMed ID: 9625339
[TBL] [Abstract][Full Text] [Related]
19. Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China.
Gao XB; Zheng Y; Yang F; Wang CH; Jiang ZH; Wu YE; Jacqz-Aigrain E; Ni SQ; Zhao W
Br J Clin Pharmacol; 2021 Mar; 87(3):1155-1164. PubMed ID: 32687613
[TBL] [Abstract][Full Text] [Related]
20. High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial.
Mohammed S; Nour I; Shabaan AE; Shouman B; Abdel-Hady H; Nasef N
Eur J Pediatr; 2015 Jul; 174(7):949-56. PubMed ID: 25644724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
